ATE240121T1 - Verfahren zur herstellung von absorbierbaren mikropartikeln - Google Patents

Verfahren zur herstellung von absorbierbaren mikropartikeln

Info

Publication number
ATE240121T1
ATE240121T1 AT99902793T AT99902793T ATE240121T1 AT E240121 T1 ATE240121 T1 AT E240121T1 AT 99902793 T AT99902793 T AT 99902793T AT 99902793 T AT99902793 T AT 99902793T AT E240121 T1 ATE240121 T1 AT E240121T1
Authority
AT
Austria
Prior art keywords
microparticles
producing
producing absorbable
absorbable microparticles
absorbable
Prior art date
Application number
AT99902793T
Other languages
English (en)
Inventor
Thomas Ciaran Loughman
Original Assignee
Kinerton Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kinerton Ltd filed Critical Kinerton Ltd
Application granted granted Critical
Publication of ATE240121T1 publication Critical patent/ATE240121T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593Polyesters, e.g. PLGA or polylactide-co-glycolide

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99902793T 1998-01-29 1999-01-25 Verfahren zur herstellung von absorbierbaren mikropartikeln ATE240121T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IE980054 1998-01-29
PCT/IE1999/000007 WO1999038535A1 (en) 1998-01-29 1999-01-25 Process for making absorbable microparticles

Publications (1)

Publication Number Publication Date
ATE240121T1 true ATE240121T1 (de) 2003-05-15

Family

ID=11041696

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99902793T ATE240121T1 (de) 1998-01-29 1999-01-25 Verfahren zur herstellung von absorbierbaren mikropartikeln

Country Status (17)

Country Link
US (1) US6555156B1 (de)
EP (1) EP1051194B9 (de)
JP (1) JP2002501907A (de)
CN (1) CN1289255A (de)
AR (1) AR014069A1 (de)
AT (1) ATE240121T1 (de)
AU (1) AU740493B2 (de)
CA (1) CA2318513A1 (de)
DE (1) DE69907870T2 (de)
DK (1) DK1051194T3 (de)
ES (1) ES2194437T3 (de)
HU (1) HUP0102373A2 (de)
IL (1) IL137349A0 (de)
NO (1) NO20003804L (de)
PL (1) PL342135A1 (de)
PT (1) PT1051194E (de)
WO (1) WO1999038535A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413539B1 (en) * 1996-10-31 2002-07-02 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
IES990700A2 (en) * 1999-08-18 2001-08-22 Kinerton Ltd Process to make a sustained release formulation
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US7186692B2 (en) 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
US7229966B2 (en) 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
EA008829B1 (ru) 2002-12-17 2007-08-31 Нэстек Фармасьютикал Кампани Инк. Композиции и способы для усовершенствованной доставки пептидов, связывающихся с y-рецепторами, которую осуществляют через слизистые оболочки, и способы лечения и предотвращения ожирения
KR20070010115A (ko) * 2003-11-13 2007-01-22 알자 코포레이션 경피전달용 조성물 및 장치
US20090023643A1 (en) * 2004-01-13 2009-01-22 Vasogenix Pharmaceuticals, Inc. Methods For Treating Acute Myocardial Infarction By Administering Calcitonin Gene Related Peptide And Compositions Containing The Same
JP2007517911A (ja) * 2004-01-13 2007-07-05 バソジェニックス ファーマシューティカルズ, インコーポレイテッド 心臓血管の適応症および腎臓の適応症に対してcgrpを使用する方法
JP2007517912A (ja) * 2004-01-13 2007-07-05 バソジェニックス ファーマシューティカルズ, インコーポレイテッド 心脈管および腎臓の適応症のための制御放出cgrp送達組成物
US7578951B2 (en) * 2004-01-27 2009-08-25 Hewlett-Packard Development Company, L.P. Method of making microcapsules utilizing a fluid ejector
WO2006044968A2 (en) 2004-10-19 2006-04-27 Achillion Pharmaceuticals, Inc. Combination therapy for treating viral infections
FR2880272A1 (fr) * 2005-01-04 2006-07-07 Jean Marc Ruiz Preparation contenant des microparticules d'un sel de polymere insoluble portant un principe actif, ainsi que son procede de fabrication
EP2118123B1 (de) 2007-01-31 2015-10-14 Dana-Farber Cancer Institute, Inc. Stabilisierte p53-peptide und deren verwendungen
EP2508531B1 (de) 2007-03-28 2016-10-19 President and Fellows of Harvard College Geheftete Polypeptide
CA2730760A1 (en) * 2008-07-16 2010-01-21 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles containing bioactive peptides
US8968787B2 (en) * 2010-05-24 2015-03-03 Micro Powders, Inc. Composition comprising biodegradable polymers for use in a cosmetic composition
MX355543B (es) 2010-08-13 2018-04-20 Aileron Therapeutics Inc Star Macrociclos peptidomiméticos.
DE102011114864A1 (de) 2011-10-05 2013-04-11 Acino Ag Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
MX358886B (es) 2011-10-18 2018-08-31 Aileron Therapeutics Inc Macrociclos peptidomimeticos.
CN104144695A (zh) 2012-02-15 2014-11-12 爱勒让治疗公司 三唑交联的和硫醚交联的拟肽大环化合物
CN107216380A (zh) 2012-02-15 2017-09-29 爱勒让治疗公司 拟肽大环化合物
JP6526563B2 (ja) 2012-11-01 2019-06-05 エイルロン セラピューティクス,インコーポレイテッド 二置換アミノ酸ならびにその調製および使用の方法
AU2015320549A1 (en) 2014-09-24 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
KR20170129879A (ko) 2015-03-20 2017-11-27 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
EP3370694A1 (de) 2015-11-06 2018-09-12 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Zusammensetzung mit einem biokompatiblen und biologisch abbaubaren polymer, nanoträger und arzneimittel sowie verfahren zur herstellung und verwendung davon

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5385738A (en) 1983-10-14 1995-01-31 Sumitomo Pharmaceuticals Company, Ltd. Sustained-release injection
EP0230654B1 (de) 1985-12-28 1992-03-18 Sumitomo Pharmaceuticals Company, Limited Arzneimittel mit verzögerter stossweiser Freisetzung
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5077049A (en) 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
CA2046830C (en) 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
CA2099376A1 (en) * 1991-01-03 1992-07-04 Henry E. Auer Stabilization of proteins by cationic biopolymers
US5366756A (en) 1992-06-15 1994-11-22 United States Surgical Corporation Method for treating bioabsorbable implant material
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
EP0712421A1 (de) * 1993-07-23 1996-05-22 Massachusetts Institute Of Technology Nanopartikel und mikropartikel aus nichtlinearen hydrophilen-hydrophoben multiblockcopolymeren
US5612052A (en) 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5874029A (en) * 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US6270700B1 (en) * 1998-07-23 2001-08-07 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Encapsulation of water soluble peptides

Also Published As

Publication number Publication date
CN1289255A (zh) 2001-03-28
IL137349A0 (en) 2001-07-24
NO20003804L (no) 2000-09-20
AR014069A1 (es) 2001-01-31
WO1999038535A1 (en) 1999-08-05
EP1051194B1 (de) 2003-05-14
PT1051194E (pt) 2003-09-30
DE69907870D1 (de) 2003-06-18
PL342135A1 (en) 2001-05-21
EP1051194A1 (de) 2000-11-15
US6555156B1 (en) 2003-04-29
AU740493B2 (en) 2001-11-08
AU2296699A (en) 1999-08-16
JP2002501907A (ja) 2002-01-22
ES2194437T3 (es) 2003-11-16
EP1051194B9 (de) 2003-11-05
HUP0102373A2 (hu) 2001-10-28
NO20003804D0 (no) 2000-07-25
CA2318513A1 (en) 1999-08-05
DE69907870T2 (de) 2004-03-04
DK1051194T3 (da) 2003-09-01

Similar Documents

Publication Publication Date Title
ATE240121T1 (de) Verfahren zur herstellung von absorbierbaren mikropartikeln
ATE297892T1 (de) Verfahren zur herstellung von azetidinonen
DE69911398D1 (de) Verfahren zur herstellung von 4-aminodiphenylaminen
DE69913666D1 (de) Verfahren zur herstellung von di-methyl-naphthalinen
DE60005779D1 (de) Verfahren zur herstellung von polyarylaten
ATE339433T1 (de) Verbessertes verfahren zur herstellung von makroliden
DE60003264D1 (de) Verfahren zur herstellung von glycerylethern
DE69914469D1 (de) Verfahren zur herstellung von hinokitiol
ATE253549T1 (de) Verfahren zur herstellung von adrenalin
DE69907148D1 (de) Verfahren zur herstellung von styrolen
DE59901552D1 (de) Verfahren zur herstellung von polyalkylenarylaten
DE50006772D1 (de) Verfahren zur herstellung von oxindolen
DE69910995D1 (de) Verfahren zur herstellung von fluorkohlenwasserstoffen
DE69825880D1 (de) Verfahren zur herstellung von eprosartan
ATE424466T1 (de) Verfahren zur herstellung von cyclodextrin
EP1208106A4 (de) Verfahren zur herstellung von aminopropyl- oder aminoalkyl-unktionalisierten polyalkyl- oder aryl-siloxanen
DE69827240D1 (de) Verfahren zur herstellung von eprosartan
DE50001895D1 (de) Verfahren zur herstellung von phosphonomethylglycin
DE69901192D1 (de) Verfahren zur herstellung von cyclopropanmethylamin
ATE233238T1 (de) Verfahren zur herstellung von 3-acyl-indolen
DE69902190D1 (de) Verfahren zur herstellung von polyester
DE59910149D1 (de) Verfahren zur herstellung von ketiminen
DE69928784D1 (de) Verfahren zur herstellung von oxazolidin-2-on-derivaten
DE69910353D1 (de) Verfahren zur herstellung von epsilon-caprolactam
DE59903764D1 (de) Verfahren zur herstellung von phytosqualan

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1051194

Country of ref document: EP

EEFA Change of the company name
REN Ceased due to non-payment of the annual fee